Patients with Non-Insulin Depending Diabetes Mellitus and Metabolic Syndrome Are Suboptimal Treated in Swiss Primary Care. (November 2013)

• Record Type: Journal Article
• Authors: Schäfer, Hans Hendrik; de Villiers, Jacob Daniel; Lotze, Ulrich; Sivukhina, Elena; Burnier, Michel; Noll, Georg; Theus, Gian-Reto; Dieterle, Thomas
• Is Part Of: Clinical and experimental hypertension. Volume 35:Number 7(2013)
• Page Start: 496
• Page End: 505
• Publication Date: 2013-11
• Subjects: Hypertension -- Chemotherapy -- Periodicals; Hypotensive agents -- Periodicals; 616.132
• DOI: 10.3109/10641963.2012.758275
• Languages: English
• ISSNs: 1064-1963

Abstract

<abstract> <title> <x xml:space="preserve">Abstract</x> </title> <p>The prevalence of <italic>complicated</italic> hypertension is increasing in America and Europe. This survey was undertaken to assess the status quo of primary care management of hypertension in patients with the high-risk comorbid diseases metabolic syndrome (MetS) and/or type 2 diabetes mellitus (non-insulin depending diabetes mellitus (NIDDM)). Data of anti-hypertensive treatment of 4594 Swiss patients were collected over 1 week. We identified patients with exclusively NIDDM (<italic>N </italic>= 95), MetS (<italic>N </italic>= 168), and both (<italic>N </italic>= 768). Target blood pressure (TBP) attainment, frequency of prescribed substance-classes, and correlations to comorbidities/end-organ damages were assessed. In addition, we analyzed the prescription of unfavorable beta-blockers (BB) and high-dose diuretics (Ds). In NIDDM, Ds (61%), angiotensin receptor blockers (ARBs) (40%), and angiotensin converting enzyme inhibitors (ACEIs) (31%) were mostly prescribed, while in MetS, drugs prevalence was Ds (68%), ARBs (48%), and BB (41%). Polypharmacy in patients with MetS correlated with body mass index; older patients (>65 years) were more likely to receive dual-free combinations. TBP was attained in 25.2% of NIDDM and in 28.7% of MetS patients. In general, low-dose Ds use was more prevalent in NIDDM and MetS, however, overall, Ds were used excessively (NIDDM: 61%, MetS: 68%), especially in single-pill combination. Patients with MetS were more likely to receive ARBs, ACEIs, CCBs, and low-dose Ds than BBs and/or high-dose Ds. Physicians recognize DM and MetS as high-risk patients, but select inappropriate drugs. Because the majority of patients may have both, MetS and NIDDM, there is an unmet need to define TBP for this specific population considering the increased risk in comparison to patients with MetS or NIDDM alone.</p> </abstract>